Skip to main content
Premium Trial:

Request an Annual Quote

Protagen, Mikrogen to Co-Develop Infectious Disease Diagnostics


By Justin Petrone

Protagen has partnered with Mikrogen to develop infectious disease tests based on Protagen's UNIarray protein chip platform.

The German firms said this week that they have conducted a feasibility study for identifying autoantibody signatures in infectious diseases that may be useful for future diagnostics.

Peter Schulz-Knappe, chief scientific officer and executive vice president of diagnostics at Protagen, said in a statement that the companies were "able to show that infection-specific reactions of the immune system are accompanied by the generation of specific autoantibodies" which he deemed "very useful" for the company's joint diagnostic program.

"The cooperation with Protagen secures Mikrogen the access to an important and novel technology platform," said Erwin Soutschek, co-founder and managing director of Neuried-based Mikrogen, in a statement. He added that the firms will jointly develop and market marker panels for differential diagnosis of relevant infectious diseases.

Dortmund-based Protagen has positioned its UNIarray platform for the development of serum-based diagnostics. The company has ongoing development programs for prostate cancer and multiple sclerosis tests. Protagen also has research programs in neurodegenerative diseases, including Parkinson and Alzheimer's, and colon, breast, pancreatic, and ovarian cancers. The firm has also launched a UNIchip line of protein microarrays for the development of antibodies.

Mikrogen offers a menu of tests for bacterial, parasitic, autoimmune, and viral diseases that are run on the Luminex xMAP platform, in PCR systems, and in enzyme-linked immunosorbent assays.

Financial and other terms of the agreement were not disclosed.

The Scan

Booster Push

New data shows a decline in SARS-CoV-2 vaccine efficacy over time, which the New York Times says Pfizer is using to argue its case for a booster, even as the lower efficacy remains high.

With Help from Mr. Fluffington, PurrhD

Cats could make good study animals for genetic research, the University of Missouri's Leslie Lyons tells the Atlantic.

Man Charged With Threatening to Harm Fauci, Collins

The Hill reports that Thomas Patrick Connally, Jr., was charged with making threats against federal officials.

Nature Papers Present Approach to Find Natural Products, Method to ID Cancer Driver Mutations, More

In Nature this week: combination of cryogenic electron microscopy with genome mining helps uncover natural products, driver mutations in cancer, and more.